Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 8/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440348 | 1.00 | EPHX2 (0.45) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL3357685 | 0.80 | CASR (0.54) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL3354878 | 0.80 | CASR (0.54) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL3357319 | 0.80 | CASR (0.54) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL3510106 | 0.75 | MTNR1A (0.53) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL2726416 | 0.75 | MTNR1A (0.72) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL10526965 | 0.74 | RIPK1 (0.49) | EPHX2RIPK1 | |
| SCHEMBL3347659 | 0.74 | BCAT2 (0.53) | EPHX2MTNR1AMTNR1BCNR1CNR2 | |
| SCHEMBL3311541 | 0.71 | RIPK1 (0.60) | EPHX2RIPK1METAP2METAP1 | |
| SCHEMBL668277 | 0.71 | RIPK1 (0.60) | EPHX2RIPK1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | EPHX2 636/4885MTNR1A 89/4885MTNR1B 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.